Doubling the infliximab dose versus halving the infusion intervals in Crohnʼs disease patients with loss of response

Abstract

Dose intensification leads to a sustained regained response in 47% of CD patients who lost response to standard infliximab dose, but halving the infusion intervals is probably not superior to dose-doubling. Given the costs and patient inconvenience incurred by an additional infusion visit, the dose-doubling strategy may be preferable to the interval-halving strategy.

Detection of infliximab levels and anti‐infliximab antibodies: a comparison of three different assays

“…[9][10][11][12] In the case of loss of response with low drug titres without antibodies, increasing the dose or shortening of the dosing interval is effective. 13 Whereas in cases of low drug titres due to anti-drug antibody formation, a switch to another anti-TNF is the preferable strategy. 14 Therapeutic drug and immunogenicity monitoring (TDIM) with early serial trough and anti-drug antibody level measurements will probably optimise anti-TNF treatment.…”

Impact of smoking on the effectiveness of TNF-α inhibitors in patients with rheumatoid arthritis or Crohn's disease

“…[7,8,[10][11][12] Some studies defined the amount of smoking as more than 5 cigarettes per day within 6 months from initiation of drug administration, [16,19,20,28,29] more than 7 cigarettes per week, [18,26] more than 1 cigarette per day, [17] or the presence of smoking without considering cigarette numbers. [13][14][15][22][23][24][25]27,[31][32][33][34] These variable smoking definitions could contribute to the discrepancy in the study results. Third, we could not separately report individual TNF-α inhibitor drugs due to the small number of studies we analyzed.…”

Rol de infliximab en enfermedad inflamatoria intestinal: Experiencia local

“…Dentro de las estrategias a usar cuando esto ocurre está aumentar la dosis de infliximab, acortar los intervalos entre las infusiones (cada seis semanas) o cambiar de terapia biológica 38 , siendo más eficaz la primera apuesta 39 . Estudios han demostrado que la evaluación de los niveles de infliximab y la presencia de anticuerpos contra infliximab permitirían definir la mejor estrategia 40 .…”